We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+56.7%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$347M
AUM Growth
+$107M
Cap. Flow
+$4.3M
Cap. Flow %
1.24%
Top 10 Hldgs %
48.52%
Holding
95
New
16
Increased
11
Reduced
34
Closed
8

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$7.34M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$6.6M
3
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$6.16M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.48M
5
LQDA icon
Liquidia Corp
LQDA
+$4.17M

Top Sells

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$4.64M
2
DXCM icon
DexCom
DXCM
+$4.37M
3
CRBP icon
Corbus Pharmaceuticals
CRBP
+$4.31M
4
CGEN icon
Compugen
CGEN
+$3.47M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.68M

Sector Composition

Rank Sector Weight
1 Healthcare 96.81%
2 Miscellaneous 3.03%
3 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STXS icon
1
Stereotaxis
STXS
$145M
$61M 17.61%
13,680,554
– –
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$17.8M 5.13%
228,089
– –
FATE icon
3
Fate Therapeutics
FATE
$291M
$16.8M 4.86%
490,861
+20,861
+4% +$622K
ARNA
4
DELISTED
Arena Pharmaceuticals Inc
ARNA
$15.4M 4.45%
245,142
+65,500
+36% +$3.6M
DRNA
5
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$11.5M 3.33%
454,236
+306,522
+208% +$6.6M
AKBA icon
6
Akebia Therapeutics
AKBA
$243M
$10.4M 2.99%
762,666
-90,872
-11% -$940K
NBIX icon
7
Neurocrine Biosciences
NBIX
$15.7B
$8.93M 2.58%
73,208
-7,000
-9% -$774K
IMMU
8
DELISTED
Immunomedics Inc
IMMU
$8.89M 2.57%
+250,905
New +$7.34M
LKFT
9
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$8.76M 2.53%
44,375
-2,000
-4% -$414K
DXCM icon
10
DexCom
DXCM
$34.3B
$8.57M 2.47%
84,552
-48,800
-37% -$4.37M
PRQR icon
11
ProQR Therapeutics
PRQR
$323M
$7.52M 2.17%
1,237,400
– –
IBB icon
12
iShares Biotechnology ETF
IBB
$10.5B
$7.5M 2.17%
54,900
-18,000
-25% -$2.29M
ARCT icon
13
Arcturus Therapeutics
ARCT
$432M
$6.96M 2.01%
149,017
+96,431
+183% +$3.32M
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$6.87M 1.98%
165,306
– –
AGTC
15
DELISTED
Applied Genetic Technologies Corporation
AGTC
$6.43M 1.86%
1,160,878
– –
BHVN
16
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.4M 1.85%
87,600
-3,000
-3% -$160K
TVRD
17
Tvardi Therapeutics
TVRD
$24.3M
$6.34M 1.83%
10,306
– –
MRSN
18
DELISTED
Mersana Therapeutics
MRSN
$6.32M 1.82%
10,807
-5,258
-33% -$1.8M
ATRC icon
19
AtriCure
ATRC
$2.47B
$5.99M 1.73%
133,229
-106,500
-44% -$4.64M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.74B
$5.33M 1.54%
+360,000
New +$5.48M
CGEN icon
21
Compugen
CGEN
$246M
$5.15M 1.49%
343,046
-256,954
-43% -$3.47M
CNST
22
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$5.14M 1.48%
+170,942
New +$6.16M
LMNX
23
DELISTED
Luminex Corp
LMNX
$5.01M 1.45%
154,091
-50,000
-24% -$1.58M
KURA icon
24
Kura Oncology
KURA
$1.13B
$4.8M 1.38%
294,260
-13,281
-4% -$192K
CSII
25
DELISTED
Cardiovascular Systems, Inc.
CSII
$4.77M 1.38%
151,200
+100,000
+195% +$3.74M
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, DAFNA Capital Management held 95 positions worth $347M, up 45% from $240M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management's Q2 2020 filing shows 16 new, 11 increased, 34 reduced and 8 closed positions. Its largest new stake was Immunomedics Inc: 250,905 shares worth $8.89M. The largest sale was AtriCure, an estimated $4.64M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Miscellaneous and Financials.

  • DAFNA Capital Management's largest Q2 2020 buy was Immunomedics Inc: 250,905 shares worth $8.89M.
  • DAFNA Capital Management added most to Dicerna Pharmaceuticals, Inc. in Q2 2020, an estimated $6.6M increase.
  • DAFNA Capital Management's biggest Q2 2020 reduction was AtriCure, cutting an estimated $4.64M.
  • DAFNA Capital Management fully exited Epizyme, Inc in Q2 2020, selling an estimated $1.64M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $347M portfolio in Q2 2020.
  • DAFNA Capital Management opened 16 new positions and closed 8 in Q2 2020.
  • DAFNA Capital Management's portfolio value rose 45% quarter-over-quarter to $347M.

Based on DAFNA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.